Dana-Farber's Belfer Institute, Sanofi-Aventis to Employ Sequencing in Cancer Drug Collaboration

The researchers will use sequencing technology at various stages in the collaboration, including target identification and validation, preclinical testing in animal models, and eventually in clinical trials, Lynda Chin, the Belfer Institute's scientific director, told In Sequence.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.